InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-18.7%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by Kelly Scott A., Président. Director active across 1 company, notably CytoDyn Inc.. Aggregated, 15 disclosures have been logged. Activity tracked since 6 August 2021. The latest transaction was filed on 30 November 2022 (Attribution). Regulator: SEC (Form 4). The full history is free.
Declarations15 total
16,927 shares0Common StockSEC:0001104659-22-123365:0
15,234 shares0Common StockSEC:0001104659-22-119979:0
17,922 shares0Common StockSEC:0001104659-22-114101:0
13,849 shares0Common StockSEC:0001104659-22-109687:0
18,793 shares0Common StockSEC:0001104659-22-105980:0
9,457 shares0Common StockSEC:0001104659-22-101258:0
11,094 shares0Common StockSEC:0001104659-22-097603:0
6,950 shares0Common StockSEC:0001104659-22-092174:0
7,492 shares0Common StockSEC:0001104659-22-086117:0
13,112 shares0Common StockSEC:0001104659-22-080836:0
13,736 shares0Common StockSEC:0001104659-22-077432:0
14,423 shares0Common StockSEC:0001104659-22-073001:0
15,592 shares0Common StockSEC:0001104659-22-069307:0
40,661 shares0Common stockSEC:0000899243-21-032395:0
40,661 shares0Common stockSEC:0000899243-21-032395
15 of 15 declarations
About Kelly Scott A.
Scott A. Kelly is the Chairman and Chief Medical Officer at CytoDyn Inc. He leads the company and oversees medical initiatives. Scott plays a key role in developing new treatments and achieving the company's objectives.
